Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3893–4892 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.